Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Novo Nordisk A/S Class B (NOVOb)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
735.0 -14.1    -1.88%
10:59:37 - Closed. Currency in DKK ( Disclaimer )
Type:  Equity
Market:  Denmark
ISIN:  DK0060534915 
S/N:  1742564000
  • Volume: 2,592,052
  • Bid/Ask: 0.0 / 0.0
  • Day's Range: 720.4 - 754.5
Novo Nordisk B 735.0 -14.1 -1.88%
IndustryPharmaceuticals
SectorHealthcare
Employees

46982

Equity Type

ORD

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Contact Information

Phone 45 44 44 88 88
Fax -

Top Executives

Name Age Since Title
Helge Lund 59 2017 Independent Chairman of the Board
Henrik Poulsen 55 2021 Vice Chairman of the Board
Jesper Thorning - 2018 Substitute Director
Kasim Kutay 57 2017 Non-Independent Director
Anders Kaae - 2018 Substitute Director
Martin W. MacKay 66 2018 Independent Director
Tanja Villumsen - 2018 Substitute Director
Andreas Fibig 60 2018 Independent Director
Karina Bonde Lenau - 2018 Substitute Director
Thomas Rantzau 50 2018 Employee Representative Non-Independent Director
Christina Law 55 2022 Director
Jeppe Fonager Christiansen 63 2013 Director
Laurence M. Debroux 53 2019 Independent Director
Sylvie L. Gregoire 61 2015 Independent Director
Mette Bojer Jensen 47 2014 Employee Non-Independent Representative Director
Elisabeth Dahl Christensen - 2022 Employee Representative Director
Liselotte Hyveled 56 2022 Employee Representative Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVOb Comments

Write your thoughts about Novo Nordisk A/S Class B
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Toby Brunt
Toby Brunt Apr 19, 2022 5:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does anyone no of a particular reason that NOVO B is going so far down today? Is it profit taking before Q1 2022 results?
Sandy SS
Sandy SS Feb 09, 2022 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New Target 825 by EOM
Sandy SS
Sandy SS Feb 09, 2022 8:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New Target 825
Terrible Investor
TerribleInvestor Nov 25, 2021 5:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Consolidating nicely for leg up to 850!🌟
Ralf Adams
Ralf Adams Feb 11, 2021 4:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
Candy Man
Candy Man Jan 14, 2021 4:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bullish??
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No. Funds are selling. Time to wait to go long...
White Wizard
White Wizard May 26, 2020 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Perfect opportunity to make short,,
Wassim Khayata
Wassim Khayata May 26, 2020 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
can you explain why please?
Jeff Heimann
Jeff Heimann May 26, 2020 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No explaning? 🤷
Tommi Nuutinen
Tommi Nuutinen May 26, 2020 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
because he has no explanation. Novo nordisk is a soli long-term stock. I know a lot about opioid treatments, and methadon is changing to lipo-methadon, wich has really only one competitor on the global field. That competitor is Camurus AB with their product buvidol. I tecommend to all investors to buy and HOLD for these two companies, because there is no other options for a opioid-replacement-care, except Suboxone, and that is going to be replaced Lipo-methadon or Buvidol, at least here in Finland. Suboxone is manufactured for Indivor Inc, by Aquestive Therapeutics, if someone wants to do a little research.
Hairol Azhar Abdul Kadir
Hairol Azhar Abdul Kadir Jan 19, 2020 2:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bullish sentiment.
Petar Petrov
Petar Petrov Jul 15, 2019 2:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why is going so low???
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email